Answers are grounded in this paper and cite their sources.
Retrospective cohort study shows improved clinical outcomes in chronic osteomyelitis with vancomycin-SC, suggesting better treatment options.
Purpose This study aimed to compare the impact on inflammatory response, clinical efficacy, and safety between vancomycin-loaded polymethylmethacrylate (PMMA) and a combination of vancomycin-loaded PMMA with vancomycin sulfate calcium (PMMA-SC) in treating chronic osteomyelitis.Methods A retrospective cohort study involved 244 patients with chronic osteomyelitis treated between January 2017 and December 2024. Patients were divided into PMMA (n = 126) and PMMA-SC (n = 118) groups. Postoperative outcomes, efficacy, inflammatory markers, quality of life, and complications were evaluated.Results The PMMA-SC group demonstrated significantly higher rates of infection control (87.29% vs. 72.22%, p = 0.004) and lower reoperation rates (7.63% vs. 21.43%, p = 0.002) compared to the PMMA group. The PMMA-SC intervention was associated with a more robust attenuation of systemic inflammation, evidenced by significantly greater reductions in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and procalcitonin (PCT) (all p < 0.05). Quality of life measures, particularly physical functioning, general health, and vitality, also favored the PMMA-SC group (p < 0.05). The overall complication rate was significantly lower in the PMMA-SC group (8.47% vs. 26.19%, p < 0.001). The multivariate logistic regression analysis demonstrated that PMMA-SC was a significant protective factor for treatment success (p < 0.05).Conclusion The combination of vancomycin sulfate calcium with PMMA was associated with improved outcomes compared to PMMA alone, potentially attributable to its association with enhanced control of infection and a more favorable modulation of the systemic inflammatory and immune response. These findings support its consideration as a promising therapeutic strategy for chronic osteomyelitis.
No takes yet. Share an insight, caveat, or question.
韩殊曼 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: